Veraxa Biotech AG - Post de-SPAC (VRXA)
Nasdaq · Pharmaceutical Preparations · Inc. V8
What they're doing
Between 2026-06-21 and 2026-09-19, public records show 1 signal for Veraxa Biotech AG - Post de-SPAC. Most notable: 2026-08-27: Baumann Oliver Rolf (director) bought $75k of stock. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-09-19 from public records.
Signals, last 12 months
- Insider purchaseBaumann Oliver Rolf (director) bought $75k of stock
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-08-27 | Baumann Oliver Rolf | director | P | 50,000 | 1.5 | $75,000 |
| 2026-08-27 | Antz Christoph Rudiger | director | P | 5,000 | 1.53 | $7,650 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.
Recent filings
- 2026-09-14 3
- 2026-09-04 424B3
- 2026-09-04 424B3
- 2026-09-04 6-K
- 2026-08-31 4
- 2026-08-31 4
- 2026-08-24 6-K
- 2026-08-20 3
- 2026-08-13 SCHEDULE 13G/A
- 2026-08-10 424B5
- 2026-08-10 424B5
- 2026-08-06 EFFECT
- 2026-08-06 EFFECT
- 2026-08-05 F-1/A
- 2026-08-05 F-1/A
- 2026-07-31 F-1
- 2026-07-31 F-1
- 2026-07-31 6-K
- 2026-07-27 6-K
- 2026-07-27 6-K